id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0062-0005,FDA,FDA-2003-E-0062,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-09-07T04:00:00Z,2006,9,,,2025-10-29T19:38:31Z,,0,0,0900006480481b10
FDA-2003-E-0062-0004,FDA,FDA-2003-E-0062,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-06-19T04:00:00Z,2006,6,,,2025-10-29T19:34:17Z,,0,0,0900006480481b0f
FDA-2003-E-0062-0003,FDA,FDA-2003-E-0062,Determination of Regulatory Review Period for Purposes of Patent Extension; CYPHER,Notice,General Notice,2006-02-15T05:00:00Z,2006,2,2006-02-03T05:00:00Z,,2025-10-29T19:30:11Z,E6-1436,0,0,0900006480481b0e